09:23 EST KKR (KKR) Genetic Dosorder L.P. announces sale of 6M shares of BridgeBio (BBIO)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma Strengthens Financial Position with Note Issuance
- BridgeBio price target raised to $46 from $45 at BofA
- Strong Launch and Strategic Initiatives Propel BridgeBio Pharma’s Growth Prospects
- Positive Outlook for BridgeBio Pharma: Strong Demand for Attruby and Promising Pipeline Fuel Buy Rating
- BridgeBio price target raised to $52 from $49 at Scotiabank